AbCellera announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center. With its T-cell engager platform, AbCellera is expanding therapeutic opportunities for this modality by generating molecules with the potential for improved efficacy and safety profiles for solid tumors and challenging targets such as peptide-MHCs. AbCellera will present four posters at AACR that demonstrate how it is leveraging its platform to develop T-cell engagers with potent tumor-cell killing and low cytokine release for multiple cancer targets.

Using data integrated from across these programs, AbCellera will present new insights into T-cell engager function. In addition, AbCellera will present data on novel CD28-binding antibodies that can be used to optimize T-cell engagers, particularly for solid tumors that are difficult to treat using current immunotherapies. Details on AbCellera?s poster presentations at AACR are as follows: Title: Functional and specific T-cell engagers against a peptide-MHC tumor target, Abstract Number: 2373, Session: Antibodies 1, Date and Time: April 8, 2024, 9:00 a.m. to 12:30 p.m. PT, Location: Section 38, Board 19.

Title: Diverse CD28-binding IgG and heavy chain-only antibodies for T-cell engager development, Abstract Number: 1859, Session: Antibody-Based Technologies and New Inhibitors, Date and Time: April 8, 2024, 9:00 a.m. to 12:30 p.m. PT, Location: Section 22, Board 3. Title: Target-dependent considerations for the design of bispecific T-cell engagers, Abstract Number: 1868, Session: Antibody-Based Technologies and New Inhibitors, Date and Time: April 8, 2024, 9:00 a.m. to 12:30 p.m. PT, Location: Section 22, Board 12. Title: Development of PSMA x CD3 T-cell engagers using an integrated, functional approach, Abstract Number: 6359, Session: Antibodies 2, Date and Time: Tuesday, April 9, 2024, 1:30 p.m. to 5:00 p.m. PT, Location: Section 41, Board 20.